Entecavir for chronic hepatitis B: A review

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 1-4

  Palumbo, Emilio ^a,b  

^a Hospital of Sondrio   (Italy)

^b NONE   (Italy)

Author keywords

Entecavir; Hepatitis B; Pharmacokinetics; Pharmacology

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; DIDANOSINE; ENTECAVIR; LAMIVUDINE; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE COURSE; DNA REPLICATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; HEPATITIS B; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38549179981     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318164f6f1     Document Type: Short Survey

References (12)

1. Chu CM, Liau YF. Natural history of chronic B virus infection: an immunopathological study. J Gastroenterol Hepatol. 1997;12:S218-S222.
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118-1129.
3. Olivero F, Santantonio T, Bellati G, et al. Long-term response to therapy of chronic anti-Hbe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol. 1999;94:1366-1372.
4. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804-810.
5. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol. 2006;46:1250-1258.
6. Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Exp Opin Biol Ther. 2006;6:913-921.
7. Zhou XX, Littler E. Nucleoside analogs as anti-HBV agents. Curr Top Med Chem. 2006;6:851-865.
8. Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol. 2006;101(Suppl 1):S19-25.
9. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123:1831-1838.
10. Sherman M, Yurdayin C, Sollano J, et al. AI463026 Behold Study Group. Entecavir for treatment of lamivudine-refractory HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049.
11. Lai CL, Shouval D, Lok AS, et al. AI463027 Behold Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
12. Chang TT, Gish RG, de Mau R, et al. AI463022 Behold Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.